{
  "docId": "019de076-9434-73df-8e70-401e13bb3d65",
  "docSlug": "692690be0ea25b83b6a4c7490ff14999",
  "documentTitle": "BioAtla | Investor Presentation Deck | 55 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 55,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a linked-circle diagram to represent the company's core pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9434-73df-8e70-401e13bb3d65/3",
  "deckHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65",
  "deckJsonHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65.json",
  "deckAnchorHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.94,
        "x": 0.03,
        "y": 0.315
      },
      "kind": "diagram",
      "text": "Proprietary technology, Broad applicability in solid tumors, Increases therapeutic window; Two Phase 2 CAB-ADCs, one Phase 2 CAB-CTLA-4 and one Phase 1 dual CAB-bispecific T-cell engager, CAB-AXL-ADC (BA3011) advancing potentially registrational trial in sarcoma as well as potentially in other indications; Prioritized pipeline, Clinical readouts for multiple indications / assets through 2024, Advancing strategic collaboration discussions; $141.3 million in cash and cash equivalents as of 09/30/23, Cash position sufficient into 2H 2025",
      "attrs": null,
      "subkind": "value-chain",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fd1a18d-e87b-4072-b29c-8046c169eade",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "BioAtla is a clinical stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABs)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1ac93c9-0ad7-4f2d-bfc4-e662cb263402",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "9c808ad6-5ada-459d-af18-4e2293800f36",
      "evidence": "The slide is titled 'BioAtla is a clinical stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABs)' and provides a brief overview.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "value-chain",
      "slug": null,
      "matchId": "56dee267-30da-4112-98eb-dc6759730520",
      "evidence": "Linked circles representing a progression of company value pillars",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}